Related Experiment Video
Updated: Aug 13, 2026
08:12
A Volumetric Method for Quantification of Cerebral Vasospasm in a Murine Model of Subarachnoid Hemorrhage
Published on: July 28, 2018
Magnesium sulfate: role as possible attenuating factor in vasospasm morbidity
Daniel Monte-Serrat Prevedello1, Joacir Graciolli Cordeiro, Andrei Leite de Morais
1Department of Neurosurgery, Hospital Nossa Senhora das Graças, Curitiba, Paraná 80810-040, Brazil.
Surgical Neurology
|January 24, 2006
Summary
Magnesium sulfate did not affect vasospasm frequency after subarachnoid hemorrhage (SAH). However, it reduced patient morbidity and length of hospital stay, suggesting a favorable impact on recovery.
Area of Science:
- Neurosurgery
- Neurology
- Critical Care Medicine
Background:
- Subarachnoid hemorrhage (SAH) frequently leads to cerebral vasospasm, a serious complication.
- Current treatments for vasospasm yield suboptimal outcomes.
- Magnesium sulfate is being re-evaluated as an adjunctive therapy for vasospasm.
Purpose of the Study:
- To investigate the efficacy of magnesium sulfate as an adjuvant therapy in patients with SAH.
- To assess the impact of magnesium sulfate on vasospasm incidence and patient outcomes.
Main Methods:
- Seventy-two patients with SAH underwent microsurgical craniotomy.
- Patients were divided into two groups: one receiving standard care (nimodipine, hypervolemic therapy, hemodilution) and another receiving standard care plus magnesium sulfate infusion.
- Serum magnesium levels were maintained at approximately double normal values in the magnesium group.
Main Results:
- No significant difference in vasospasm incidence was observed between the groups.
- Patients receiving magnesium sulfate experienced a shorter hospitalization duration compared to the control group.
- No statistical differences were found in demographic or clinical admission grades between the groups.
Conclusions:
- Magnesium sulfate did not alter the frequency of vasospasm following SAH.
- Magnesium sulfate administration was associated with reduced morbidity and shorter hospital stays in SAH patients.
- Further research may clarify the role of magnesium in mitigating SAH complications.
Related Concept Videos
01:16Vascular Spasm
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...
01:29Spasmolytic Agents: Chemical Classification
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:21Skeletal Muscle Relaxants: Adverse Effects
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
01:28Classification of Skeletal Muscle Relaxants
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...